Awar-Awar Leaves Ethanolic Extract Sinergistically Enhances Cytotoxic Effect of Doxorubicin on T47D Breast Cancer Cells

Authors

  • RATIH HARDIKA PRATAMA UNIVERSITAS GADJAH MADA ,
  • YURISTA GILANG IKHTIARSYAH UNIVERSITAS GADJAH MADA ,
  • ANINDYAJATI ANINDYAJATI UNIVERSITAS GADJAH MADA ,
  • ADTYA FITRIASARI UNIVERSITAS GADJAH MADA ,
  • MUTHI IKAWATI UNIVERSITAS GADJAH MADA ,
  • EDY MEIYANTO UNIVERSITAS GADJAH MADA ,

Keywords:

awar-awar leaves ethanolic extract, doxorubicin, combination, T47D cells

Abstract

Awar awar leaves which have not been optimally utilized in cancer treatment, are potential to be used in combination with doxorubicin (DOX), an agent used for chemotherapy. The aim of this experiment is to find out cytotoxic effect of awar-awar leaves ethanolic extract (ALE) and its combination with DOX towards breast cancer cells of T47D. ALE was prepared by macerating the dried-leaves powder with ethanol 70%. The cytotoxic effect of ALE toward breast cancer cells was tested employing MTT assay to the treatments both as a single agent and as a combination with doxorubicin (ALE DOX). The cytotoxicity was determined as IC50 value, while effectiveness of combination was measured by combination index (CI) to determine whether the effect is synergic, addictive, or antagonistic. Cytotoxic tests on single treatment ALE for a period of 24 hours resulted to a cytotoxic effect with IC so value of 13 µg/mL. ALE-DOX combination showed synergistic effect (CI < 1) on the concentration of 4.88 µg/mL (ALE) and 3.75 nM (DOX). The results showed that ALE is potential to be used as doxorubicin co-chemotherapeutic agent in breast cancer therapy.

References

Downloads

Published

2011-04-30

Issue

Vol. 9 No. 1 (2011): JIFI

Section

Articles

License

Licencing
All articles in Jurnal Ilmu Kefarmasian Indonesia are an open-access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which permits unrestricted non-commercial used, distribution and reproduction in any medium.

This licence applies to Author(s) and Public Reader means that the users mays :

  • SHARE:
    copy and redistribute the article in any medium or format
  • ADAPT:
    remix, transform, and build upon the article (eg.: to produce a new research work and, possibly, a new publication)
  • ALIKE:
    If you remix, transform, or build upon the article, you must distribute your contributions under the same license as the original.
  • NO ADDITIONAL RESTRICTIONS:
    You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

It does however mean that when you use it you must:

  • ATTRIBUTION: You must give appropriate credit to both the Author(s) and the journal, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

You may not:

  • NONCOMMERCIAL: You may not use the article for commercial purposes.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.